| Literature DB >> 35953795 |
Ryosuke Imai1, Daisuke Yamada2, Yutaka Tomishima3, Tomoaki Nakamura3, Clara So3, Shosei Ro3, Kohei Okafuji3, Atsushi Kitamura3, Torahiko Jinta3, Naoki Nishimura3.
Abstract
BACKGROUND: Although diffuse alveolar damage (DAD) is a histopathological hallmark of acute respiratory distress syndrome (ARDS), its detection without lung biopsy is challenging. In patients with ARDS, the specificity of the Berlin definition to diagnose DAD as a reference standard is not adequately high, making it difficult to adequately diagnose DAD. The purpose of this study was to investigate the relationship between DAD and clinical findings, including KL-6 and geographic appearance, in ARDS patients and to identify more specific diagnostic criteria for DAD.Entities:
Keywords: Acute respiratory distress syndrome; Chest high-resolution computed tomography; Diffuse alveolar damage; Geographic appearance; KL-6
Mesh:
Year: 2022 PMID: 35953795 PMCID: PMC9367020 DOI: 10.1186/s12890-022-02102-y
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.320
Fig. 1A 70-year-old man, who developed respiratory failure during antibiotic therapy for Staphylococcus aureus bacteremia, was diagnosed with acute respiratory distress syndrome. High-resolution CT at diagnosis showed bilateral diffuse reticulation with geographic appearance (black arrows), well-circumscribed infiltrations partially spared in secondary pulmonary lobule units, and bilateral pleural effusions. Although the patient was placed on mechanical ventilation in addition to being administered antibiotics, he passed away 4 days after diagnosis, and autopsy was performed. Pathological findings of the lungs revealed hyaline membrane formation along dilated alveolar ducts and alveoli, with shrinkage of adjacent alveoli and hyperplasia of type II pneumocytes, representing the exudate phase of diffuse alveolar damage
Demographic and clinical characteristics between patients with DAD and non-DAD
| Characteristic | Total (n = 27) | DAD (n = 18) | Non-DAD (n = 9) | |
|---|---|---|---|---|
| Age, years | 79 (62–92) | 79 (62–92) | 80 (66–91) | 0.757 |
| Male | 19 (70) | 13 (72) | 6 (67) | 1.000 |
| BMI | 22.1 (16.4–28.8) | 21.9 (17.1–28.8) | 22.6 (16.4–26.2) | 0.471 |
| PaO2/FiO2 | 142 (48–258) | 142 (48–203) | 142 (60–258) | 0.877 |
| APACHE II score | 29 (18–44) | 28 (21–41) | 34 (18–44) | 0.469 |
| Severity at diagnosis | 0.655 | |||
| Mild | 2 (7) | 1 (5) | 1 (11) | |
| Moderate | 19 (70) | 12 (67) | 17 (78) | |
| Severe | 6 (22) | 5 (28) | 1 (11) | |
| Ventilation | 0.683 | |||
| Noninvasive ventilation | 10 (37) | 6 (33) | 4 (44) | |
| Mechanical ventilation | 17 (63) | 12 (67) | 5 (56) | |
| Underlying diseases | ||||
| Diabetes mellitus | 6 (22) | 3 (17) | 3 (33) | 0.367 |
| Malignance | 6 (22) | 3 (17) | 3 (33) | 0.367 |
| Immunosuppression | 5 (19) | 2 (11) | 3 (33) | 0.295 |
| End stage renal disease | 1 (4) | 0 (0) | 1 (11) | 0.333 |
| Primary risk factor of ARDS | 0.916 | |||
| Pneumonia | 15 (56) | 10 (56) | 5 (56) | |
| Connective tissue disease | 4 (15) | 3 (17) | 1 (11) | |
| Drug-induced | 3 (11) | 1 (6) | 2 (22) | |
| Sepsis | 2 (7) | 1 (6) | 1 (11) | |
| Malignancy | 1 (4) | 1 (6) | 0 (0) | |
| Aspiration | 1 (4) | 1 (6) | 0 (0) | |
| Radiation | 1 (4) | 1 (6) | 0 (0) | |
| Duration of ARDS before death, d | 18 (1–51) | 18 (4–51) | 18 (1–40) | 0.410 |
| Laboratory data at diagnosis | ||||
| WBC, per mm3 | 10,300 (300–37,800) | 11,200 (300–37,800) | 10,300 (2,300–30,000) | 0.877 |
| CRP, mg/dL | 13.6 (3.5–39.5) | 15.3 (3.5–39.5) | 11.2 (5.5–21.2) | 0.291 |
| Albumin, g/dL | 2.5 (1.4–3.3) | 2.5 (1.4–3.2) | 2.4 (1.4–3.3) | 0.570 |
| Creatinine, mg/dL | 1.14 (0.27–4.64) | 1.13 (0.50–4.56) | 1.33 (0.27–4.64) | 0.471 |
| LDH, U/L | 343 (212–1,192) | 425 (212–1,192) | 317 (233–705) | 0.345 |
| KL-6*, U/mL | 413 (194–1,780) | 760 (194–1,780) | 322 (229–1,322) | 0.090 |
| KL-6* > 500 U/mL | 12 (44) | 11 (65) | 1 (11) | 0.014 |
| Treatment | ||||
| Corticosteroid administration | 14 (52) | 10 (56) | 4 (44) | 0.695 |
| Methylprednisolone pulse therapy† | 13 (48) | 10 (56) | 3 (33) | 0.420 |
| Autopsy findings | ||||
| Weight of two lungs, g | 1,380 (545–4,605) | 1,455 (675–4,605) | 1,100 (545–2,375) | 0.143 |
| DAD | 18 (67) | 18 (100) | – | |
| Organizing pneumonia | 7 (26) | – | 7 (78) | |
| Pulmonary hemorrhage | 2 (7) | – | 2 (22) | |
Continuous variables are expressed as medians (ranges), and categorical data are expressed as n (%)
APACHE Acute Physiology and Chronic Health Evaluation, BMI body mass index, CRP C-reactive protein, DAD diffuse alveolar damage, KL-6 Krebs von den Lungen-6, LDH lactate dehydrogenase, PaO/FiO arterial oxygen partial pressure/fractional inspired oxygen, WBC white blood cell
*Total n = 26; one case of non-DAD had a missing value
† ≥ 500 mg/day for 3 days
HRCT findings at onset between the patients with DAD and non-DAD
| HRCT findings | Total (n = 27) | DAD (n = 18) | Non-DAD (n = 9) | |
|---|---|---|---|---|
| Ground-glass opacity | 27 (100) | 18 (100) | 9 (100) | NA |
| Consolidation | 19 (70) | 14 (78) | 5 (56) | 0.375 |
| Fibrosis | 5 (19) | 3 (17) | 2 (22) | 1.000 |
| Honeycombing | 1 (4) | 1 (6) | 0 (0) | 1.000 |
| Traction bronchiectasis | 20 (74) | 14 (78) | 6 (67) | 0.653 |
| Volume loss | 23 (85) | 16 (89) | 7 (78) | 0.582 |
| Geographic appearance | 21 (78) | 16 (89) | 4 (44) | 0.023 |
Data are expressed as n (%)
HRCT high-resolution computed tomography, DAD diffuse alveolar damage
Sensitivity and specificity of KL-6 and geographic appearance for the diagnosis of DAD
| Sensitivity, % (95% CI) | Specificity, % (95% CI) | Positive likelihood ratio (95% CI) | Negative likelihood ratio (95% CI) | |
|---|---|---|---|---|
| KL-6 > 500 U/mL | 61 (36–83) | 89 (52–100) | 5.5 (0.8–36.2) | 0.4 (0.2–0.8) |
| Geographic appearance | 89 (65–99) | 56 (21–86) | 2.0 (0.9–4.2) | 0.2 (0.05–0.8) |
| Geographic appearance and | ||||
| KL-6 > 500 U/mL | 56 (31–79) | 100 (56–100) | NA | 0.4 (0.3–0.7) |
CI confidence interval, KL-6 Krebs von den Lungen-6